Grupo Zendal | Prensa

El Grupo Zendal

Zendal Portugal

Biofarmacéuticos

Ediciones anteriores

28 · 06 · 2024Zendal Group launches the 5th edition of its International Zendal Awards for human and animal health projects

20 · 06 · 2024Biofabri and TBVI sign a contract with the European Health and Digital Executive Agency to accelerate the final development of the new TB vaccine MTBVAC

23 · 03 · 2024MTBVAC, the first vaccine against Tuberculosis derived from a human source, begins clinical trials in adults in India.

18 · 03 · 2024ZENDAL launches the first DNA technology vaccine against canine leishmaniasis

24 · 01 · 2024VETIA ANIMAL HEALTH STRENGTHENS ITS PORTFOLIO

19 · 12 · 2023IAVI and Zendal announce funding for efficacy trial of promising TB vaccine candidate in Africa

14 · 12 · 2023International research consortium receives highly endowed Horizon Europe funding for the development of vaccines against Marburg viruses.

20 · 11 · 2023Innovative project against bacterial resistance and a protective vaccine for bees, winners of the Zendal Awards

25 · 10 · 2023Zendal launches its human health vaccine manufacturing plant in the Portuguese town of Paredes de Coura

02 · 10 · 2023The jury for the Zendal Awards, which will be presented at a gala in Vigo on November 16, has been officially established.

13 · 07 · 2023Germany issues award to IAVI to support development of the MTBVAC tuberculosis vaccine candidate

03 · 07 · 2023Zendal and Reig Jofre appointed by the EU to ensure vaccine production capacity in Europe in case of future health emergencies

1
2
3
4